196 related articles for article (PubMed ID: 23230896)
1. Comparison of 211At-PRIT and 211At-RIT of ovarian microtumors in a nude mouse model.
Frost SH; Bäck T; Chouin N; Hultborn R; Jacobsson L; Elgqvist J; Jensen H; Albertsson P; Lindegren S
Cancer Biother Radiopharm; 2013 Mar; 28(2):108-14. PubMed ID: 23230896
[TBL] [Abstract][Full Text] [Related]
2. In vivo distribution of avidin-conjugated MX35 and (211)At-labeled, biotinylated poly-L-lysine for pretargeted intraperitoneal α-radioimmunotherapy.
Frost SH; Bäck T; Chouin N; Jensen H; Hultborn R; Jacobsson L; Lindegren S
Cancer Biother Radiopharm; 2011 Dec; 26(6):727-36. PubMed ID: 22087606
[TBL] [Abstract][Full Text] [Related]
3. Alpha-radioimmunotherapy of intraperitoneally growing OVCAR-3 tumors of variable dimensions: Outcome related to measured tumor size and mean absorbed dose.
Elgqvist J; Andersson H; Bäck T; Claesson I; Hultborn R; Jensen H; Johansson BR; Lindegren S; Olsson M; Palm S; Warnhammar E; Jacobsson L
J Nucl Med; 2006 Aug; 47(8):1342-50. PubMed ID: 16883015
[TBL] [Abstract][Full Text] [Related]
4. Comparison of therapeutic efficacy and biodistribution of 213Bi- and 211At-labeled monoclonal antibody MX35 in an ovarian cancer model.
Gustafsson AM; Bäck T; Elgqvist J; Jacobsson L; Hultborn R; Albertsson P; Morgenstern A; Bruchertseifer F; Jensen H; Lindegren S
Nucl Med Biol; 2012 Jan; 39(1):15-22. PubMed ID: 21958859
[TBL] [Abstract][Full Text] [Related]
5. Administered activity and metastatic cure probability during radioimmunotherapy of ovarian cancer in nude mice with 211At-MX35 F(ab')2.
Elgqvist J; Andersson H; Bernhardt P; Bäck T; Claesson I; Hultborn R; Jensen H; Johansson BR; Lindegren S; Olsson M; Palm S; Warnhammar E; Jacobsson L
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1228-37. PubMed ID: 17145538
[TBL] [Abstract][Full Text] [Related]
6. 211At radioimmunotherapy of subcutaneous human ovarian cancer xenografts: evaluation of relative biologic effectiveness of an alpha-emitter in vivo.
Bäck T; Andersson H; Divgi CR; Hultborn R; Jensen H; Lindegren S; Palm S; Jacobsson L
J Nucl Med; 2005 Dec; 46(12):2061-7. PubMed ID: 16330571
[TBL] [Abstract][Full Text] [Related]
7. Radioimmunotherapy of nude mice with intraperitoneally growing ovarian cancer xenograft utilizing 211At-labelled monoclonal antibody MOv18.
Andersson H; Lindegren S; Back T; Jacobsson L; Leser G; Horvath G
Anticancer Res; 2000; 20(1A):459-62. PubMed ID: 10769696
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with (211)At-labeled monoclonal antibody MX35.
Elgqvist J; Andersson H; Bäck T; Hultborn R; Jensen H; Karlsson B; Lindegren S; Palm S; Warnhammar E; Jacobsson L
J Nucl Med; 2005 Nov; 46(11):1907-15. PubMed ID: 16269606
[TBL] [Abstract][Full Text] [Related]
9. Intraperitoneal alpha-radioimmunotherapy in mice using different specific activities.
Elgqvist J; Andersson H; Haglund E; Jensen H; Kahu H; Lindegren S; Warnhammar E; Hultborn R
Cancer Biother Radiopharm; 2009 Aug; 24(4):509-13. PubMed ID: 19694586
[TBL] [Abstract][Full Text] [Related]
10. Cure of Human Ovarian Carcinoma Solid Xenografts by Fractionated α-Radioimmunotherapy with
Bäck T; Chouin N; Lindegren S; Kahu H; Jensen H; Albertsson P; Palm S
J Nucl Med; 2017 Apr; 58(4):598-604. PubMed ID: 27688477
[TBL] [Abstract][Full Text] [Related]
11. Pretargeted Radioimmunotherapy of Prostate Cancer with an Anti-TROP-2×Anti-HSG Bispecific Antibody and a (177)Lu-Labeled Peptide.
van Rij CM; Frielink C; Goldenberg DM; Sharkey RM; Lütje S; McBride WJ; Oyen WJ; Boerman OC
Cancer Biother Radiopharm; 2014 Oct; 29(8):323-9. PubMed ID: 25226447
[TBL] [Abstract][Full Text] [Related]
12. Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts.
Subbiah K; Hamlin DK; Pagel JM; Wilbur DS; Meyer DL; Axworthy DB; Mallett RW; Theodore LJ; Stayton PS; Press OW
J Nucl Med; 2003 Mar; 44(3):437-45. PubMed ID: 12621012
[TBL] [Abstract][Full Text] [Related]
13. Fractionated radioimmunotherapy of intraperitoneally growing ovarian cancer in nude mice with 211At-MX35 F(ab')2: therapeutic efficacy and myelotoxicity.
Elgqvist J; Andersson H; Bäck T; Claesson I; Hultborn R; Jensen H; Lindegren S; Olsson M; Palm S; Warnhammar E; Jacobsson L
Nucl Med Biol; 2006 Nov; 33(8):1065-72. PubMed ID: 17127181
[TBL] [Abstract][Full Text] [Related]
14. Glomerular filtration rate after alpha-radioimmunotherapy with 211At-MX35-F(ab')2: a long-term study of renal function in nude mice.
Bäck T; Haraldsson B; Hultborn R; Jensen H; Johansson ME; Lindegren S; Jacobsson L
Cancer Biother Radiopharm; 2009 Dec; 24(6):649-58. PubMed ID: 20025544
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the therapeutic efficacy of 211At- and 131I-labelled monoclonal antibody MOv18 in nude mice with intraperitoneal growth of human ovarian cancer.
Andersson H; Palm S; Lindegren S; Bäck T; Jacobsson L; Leser G; Horvath G
Anticancer Res; 2001; 21(1A):409-12. PubMed ID: 11299770
[TBL] [Abstract][Full Text] [Related]
16. α- Versus β-Emitting Radionuclides for Pretargeted Radioimmunotherapy of Carcinoembryonic Antigen-Expressing Human Colon Cancer Xenografts.
Heskamp S; Hernandez R; Molkenboer-Kuenen JDM; Essler M; Bruchertseifer F; Morgenstern A; Steenbergen EJ; Cai W; Seidl C; McBride WJ; Goldenberg DM; Boerman OC
J Nucl Med; 2017 Jun; 58(6):926-933. PubMed ID: 28232604
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic efficacy of astatine-211-labeled trastuzumab on radioresistant SKOV-3 tumors in nude mice.
Palm S; Bäck T; Claesson I; Danielsson A; Elgqvist J; Frost S; Hultborn R; Jensen H; Lindegren S; Jacobsson L
Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):572-9. PubMed ID: 17869670
[TBL] [Abstract][Full Text] [Related]
18. Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2--a phase I study.
Andersson H; Cederkrantz E; Bäck T; Divgi C; Elgqvist J; Himmelman J; Horvath G; Jacobsson L; Jensen H; Lindegren S; Palm S; Hultborn R
J Nucl Med; 2009 Jul; 50(7):1153-60. PubMed ID: 19525452
[TBL] [Abstract][Full Text] [Related]
19. Alpha radioimmunotherapy using
Cheal SM; McDevitt MR; Santich BH; Patel M; Yang G; Fung EK; Veach DR; Bell M; Ahad A; Vargas DB; Punzalan B; Pillarsetty NVK; Xu H; Guo HF; Monette S; Michel AO; Piersigilli A; Scheinberg DA; Ouerfelli O; Cheung NV; Larson SM
Theranostics; 2020; 10(25):11359-11375. PubMed ID: 33052220
[TBL] [Abstract][Full Text] [Related]
20. Radiolabeled Antibodies Against Müllerian-Inhibiting Substance Receptor, Type II: New Tools for a Theranostic Approach in Ovarian Cancer.
Deshayes E; Ladjohounlou R; Le Fur P; Pichard A; Lozza C; Boudousq V; Sevestre S; Jarlier M; Kashani R; Koch J; Sosabowski J; Foster J; Chouin N; Bruchertseifer F; Morgenstern A; Kotzki PO; Navarro-Teulon I; Pouget JP
J Nucl Med; 2018 Aug; 59(8):1234-1242. PubMed ID: 29674421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
